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During a 1-year period, the prevalence of thymidine-dependent (TD) Staphylococcus aureus in patients at two
geographically distinct cystic fibrosis (CF) centers was determined. Of 200 CF patients who had their
respiratory secretions cultured, 95 harbored S. aureus, and 20 (21%) had TD S. aureus as their predominant
staphylococcal isolate. All 20 TD S. aureus-positive patients had received trimethoprim-sulfamethoxazole for
an average of 30.9 months. It was also observed that TD S. aureus exhibited aberrant colony morphologies or
did not grow on media commonly used in CF centers for S. aureus isolation, suggesting that this organism could
be missed by routine culture methods. In contrast, all 20 isolates had typical staphylococcal morphology on
mannitol salt agar after 48 h of incubation. Mannitol salt agar is recommended for primary isolation of TD S.
aureus.
Staphylococcus aureus continues to be an important res-
piratory tract pathogen in patients with cystic fibrosis (CF).
Hoiby (2) recently reported that S. aureus was involved in
20% of all pulmonary exacerbations in CF patients. These
patients are often treated with prophylactic antimicrobial
agents, in part, to prevent pulmonary complications associ-
ated with S. aureus infection. In a recent survey of 114 CF
centers in the United States, 0. Tablan (personal communi-
cation) found that in 58 centers (51%), trimethoprim-
sulfamethoxazole (TMP-SMX) was a frequently used pro-
phylactic agent. Although most strains of S. aureus are
exquisitely susceptible to TMP-SMX (7), several investiga-
tors in Great Britain (3, 8; R. George and R. E. Hewling,
Letter, Lancet ii:1081, 1977; R. W. Lacey and E. Lewis,
Letter, Br. Med. J. 4:165, 1973) have described the emer-
gence of TMP-SMX-resistant S. aureus isolates in CF pa-
tients during or after therapy with this agent. Resistance of
these organisms is presumably due to their ability to bypass
the folic acid synthetic pathway, which is blocked by TMP-
SMX, and directly procure thymidine, a major end product
of this pathway, from their environment (11). Because a
medium with a low thymidine content will not support the
growth of these S. aureus strains, these organisms are
referred to as thymidine dependent (TD). We present data on
the prevalence of TD S. aureus in two CF centers over a
period of 1 year. We also examined the ability of TD S.
aureus to grow on laboratory media commonly used for the
isolation of S. aureus in CF centers.
MATERIALS AND METHODS
Patients studied. All individuals with CF seen at the CF
centers of either the University of North Carolina, Chapel
Hill, or the University of Oklahoma Children's Memorial
Hospital, Oklahoma City, were included in this study if they
had cultures of respiratory secretions done between 15 May
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1985 and 15 May 1986. The patients ranged in age from 0.5 to
37 years. Charts were available for 90 of 95 patients from
whom S. aureus was recovered. They were reviewed to
determine the history of previous antimicrobial therapy with
TMP-SMX.
Culture techniques. Respiratory secretions, including spu-
tum, bronchial washings, deep pharyngeal swabs, tracheal
aspirates, and Bartlett bronchial brushings were routinely
cultured to ensure the specific recovery of Haemophilus
influenza, Pseudomonas aeruginosa, Pseudomonas
cepacia, enteric and glucose-nonfermenting gram-negative
rods, Streptococcus pneumoniae, and S. aureus. At the
University of North Carolina, cultures were done with horse
blood agar, colistin-nalidixic acid (CNA) agar, MacConkey
agar (Difco Laboratories, Detroit, Mich.), PC medium, and
mannitol salt agar. Plates were incubated at 35°C and were
examined daily for 3 days for the pathogens already listed.
At Children's Memorial Hospital, the cultures were per-
formed with horse blood agar (heart infusion base; Difco)
containing 100 ,ug of bacitracin (The Upjohn Co., Kalama-
zoo, Mich.); 5% sheep Columbia blood agar (Columbia base;
Difco); MacConkey agar; OF base with polymyxin,
bacitracin, and lactose (OFPBL) agar (Remel, Lenexa,
Kans.); and mannitol salt agar. PC medium and OFPBL agar
are selective and differential media used for the isolation of
P. cepacia (1).
S. aureus isolates were recognized to be TD if they grew
on mannitol salt agar or Columbia blood agar but failed to
grow for susceptibility testing on Mueller-Hinton agar or
broth. Thymidine dependence was confirmed by the growth
of these isolates on Mueller-Hinton agar which was first
swabbed with a 1% solution of thymidine. All TD S. aureus
organisms were confirmed as S. aureus on the basis of a
positive catalase and coagulase test and fermentation on
mannitol salt agar. Antimicrobial susceptibility testing was
done by disk diffusion (6).
Growth response studies. To study the growth response on
media commonly used to isolate S. aureus from respiratory
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TABLE 1. Comparison of characteristics of TMP-SMX therapy
Age of No. of patients Duration of
Species patient at receiving TMP-SMXisolation TMP-SMX/total therapy
(yr)a no. in group (mo)a
TD S. aureus 14.2 (20) 20/20 30.9 (18)
Non-TD S. aureus 10.5 (75)b 19/70c 11.0 (19)d
a Values in parentheses are the total number of individuals.
b p O.l.
c P 0.0001.
d p = 0.0067.
secretions of CF patients, 15 isolates of TD S. aureus were
selected. The media chosen for study were determined in
part by reviewing the results of a survey of 114 CF centers in
which media used to culture respiratory secretions of CF
patients were outlined (O. Tablan, personal communica-
tion). The media studied were Mueller-Hinton agar, choco-
late agar, phenylethyl alcohol (PEA) agar, CNA agar, 5%
horse blood agar, mannitol salt agar, 5% sheep blood agar,
and 5% sheep blood agar supplemented with 1 or 100 ,ug of
thymidine (Calbiochem-Behring, La Jolla, Calif.) per ml.
Mueller-Hinton, mannitol salt, and CNA agars were pur-
chased from Difco Laboratories. PEA agar and basal media
for chocolate agar (GC base) and for horse and sheep blood
agars (Trypticase soy agar) were purchased from BBL
Microbiology Systems, Cockeysville, Md.
Isolates were grown overnight in Trypticase soy broth
(BBL), adjusted to a 0.5 McFarland standard with Mueller-
Hinton broth (BBL), and diluted 1:10,000 in Mueller-Hinton
broth. One hundred microliters was then inoculated onto
each medium and spread with a glass rod. The plates were
incubated at 35°C and were examined daily for up to 3 days.
The colony morphology of each isolate on each medium was
compared with that of the isolate on 5% sheep blood agar
supplemented with 100 ,ug of thymidine per ml and with that
of S. aureus ATCC 25923 growing on the same medium.
Isolates showing typical S. aureus morphology when com-
pared with the two controls were said to have normal
growth. All other colony morphologies were considered
abnormal growth.
Thymine and thymidine dependence studies, Five TD S.
aureus isolates (three from the University of North Carolina,
two from Children's Memorial Hospital) were studied to
determine their thymine and thymidine growth require-
ments. The organisms were grown overnight in Trypticase
soy broth and centrifuged; the pellets were washed twice
with 0.01 M phosphate-buffered saline, pH 7.0, and were
suspended to a density equal to that of a 0.5 McFarland
standard. The washed isolates were inoculated to give a final
dilution of 1:1,000 into Mueller-Hinton broth alone or were
supplemented with a doubling dilution of thymine (Sigma
Chemical Co., St. Louis, Mo.) or thymidine ranging from 0.2
to 100 ,ug/ml. Growth was measured by monitoring the
changes in optical density at 670 nm for 24 h with the
research module of the Advantage Microbiology System
(Abbott Laboratories, North Chicago, Ill.). In this system,
isolates were grown at 35°C with continuous shaking. An
optical density change of 0.05 or greater was considered
positive growth.
Statistical methods. The Student t test was used to com-
pare the age and duration of TMP-SMX therapy in patients
with and without TD S. aureus. The x2 test was used to
compare the use of TMP-SMX therapy in patients with and
without TD S. aureus (9).
RESULTS
We cultured respiratory secretions from 200 CF patients at
various times over a 1-year period. S. aureus was recovered
from 95 individuals (48%). Of these 95 patients, 20 (21%) had
TD S. aureus as their predominant isolate on either mannitol
salt agar or Columbia blood agar. TD S. aureus was consis-
tently recovered from several patients from whom multiple
cultures were Qbtained. The isolates from these 20 patients
were, by definition, all resistant to TMP-SMX. Otherwise,
their in vitro susceptibility was typical for S. aureus, in that
the isolates were resistant to penicillin and susceptible to
beta-lactamase-stable penicillins, gentamicin, chloramphen-
icol, clindamycin, erythromycin, cephalosporins, and van-
comycin. Charts were available for review on 90 of 95
patients. A summary of these data is found in Table 1.
Patients from whom TD S. aureus was recovered were not
significantly older than patients harboring non-TD S. aureus
(P = 0.1). All 20 TD S. aureus-positive patients had received
TMP-SMX. The duration of TMP-SMX therapy in this
population ranged from 3 months to over 8 years. Many of
these patients received TMP-SMX intermittently, usually
during the winter months or when respiratory symptoms
worsened. In contrast, only 19 of 70 (27%) CF patients with
non-TD S. aureus were receiving TMP-SMX. The average
duration of TMP-SMX therapy, 10.6 months, in the patients
harboring non-TD S. aureus was approximately one-third
the duration of therapy for the TD S. aureus-positive pa-
tients.
We next examined the ability of nine different media to
support the growth of 15 isolates of TD S. aureus. Six of the
media, 5% sheep blood agar, PEA agar, CNA agar, choco-
late agar, horse blood agar, and mannitol salt agar, have
been reported to be used for the primary isolation of patho-
gens, especially gram-positive ones, from the respiratory
secretions of CF patients in the United States (O. Tablan,
personal communication). The results demonstrate the ca-
pacity of the nine different media to support growth of the 15
TD S. aureus strains (Table 2). Typical S. aureus colonies
were seen on both 5% sheep blood agar supplemented with
100 ,ug of thymidine per ml and mannitol salt agar after 48 h
of incubation. Growth of some TD S. aureus isolates was
somewhat delayed after 24 h of incubation on mannitol salt
agar compared with that of the control strain. Not surpris-
ingly, none of the 15 isolates grew on Mueller-Hinton agar.
Only 2 of 15 isolates grew on 5% horse blood agar, and these
organisms grew as pinpoint colonies after 72 h of incubation.
Although 13 of 15 isolates grew on PEA agar, these colonies
TABLE 2. Growth response of 15 TD strains of S. aureus on
media used for isolation of S. aureus
No. of strains responding with:
Agar Normal Abnormal
growth growth No growth
Mueller-Hinton 0 0 15
Horse blood 0 2 13
PEA 0 13 2
CNA 5 10 0
Chocolate 3 12 0
Mannitol salt 15 0 0
Sheep blood 7 8 0
Sheep blood + 1 ,ug of 12 3 0
thymidine per ml
Sheep blood + 100 xug of 15 0 0
thymidine per ml
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were almost always pinpoint after 72 h. Colony morphology
varied greatly on CNA agar, chocolate agar, 5% sheep blood
agar, and 5% sheep blood agar supplemented with 1 ,ug of
thymidine per ml. On CNA agar, colony morphology among
the different isolates varied from the typical S. aureus
morphology for some isolates to small staphylococcuslike
colonies or streptococcuslike colonies for other isolates.
Although 5% sheep blood agar grew more isolates of normal
appearance than did CNA agar (7 versus 5), the variations in
growth and morphology were very similar to those on CNA
agar for 8 of the 15 isolates. The greatest variation in TD S.
aureus colony morphology was seen on chocolate agar.
Three of the isolates had normal colony morphology, while
the other twelve isolates showed colony morphology which
resembled that of streptococci or hemophili. The three
isolates which showed abnormal morphology on 5% sheep
blood agar supplemented with 1 ,ug of thymidine per ml had
a fried-egg appearance. Similar morphology was also seen on
5% sheep blood and chocolate agars for these isolates.
Thymine and thymidine requirements were studied by
using five TD S. aureus. All five isolates grew at 0.2 ,ug of
thymidine per ml. However, the C-1003 isolate appeared to
undergo lysis at low concentrations of thymidine (c6.25
,ug/ml), whereas at higher thymidine concentrations (-25
,ug/ml), this did not occur (Fig. 1). This growth curve was
representative of all five isolates tested. Unlike thymidine,
the thymine requirements of the five TD S. aureus isolates
varied from 0.2 ,ug/ml (two isolates) to 6.25 ,ug/ml (two
isolates) to 100 ,ug/ml (one isolate). Lysis did not appear to
occur at the lower concentration of thymine at which there
was growth (Fig. 2). In addition, growth was either delayed
(Fig. 2) or did not occur at the lower concentrations of
thymine tested.
DISCUSSION
Respiratory failure due to chronic lung infection continues
to be the major cause of premature death in individuals with
CF. In the preantibiotic era, S. aureus lung infection was an
important cause of death in CF patients. The advent of
effective antistaphylococcal antimicrobial therapy was a
major factor in the increased life span presently seen in these
patients (12). A common strategy used in the care of CF
patients is the administration of long-term prophylactic oral
antimicrobial agents, including, but not limited to, tetracy-
cline, chloramphenicol, TMP-SMX, and certain cephalospo-
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FIG. 1. Growth response of TD S. aureus isolate C-1003 to
thymidine supplementation of Mueller-Hinton broth, as seen by








FIG. 2. Growth response of TD S. aureus isolate C-716 to
thymine supplementation of Mueller-Hinton broth, as seen by
changes in the optical density at 670 nm (OD670).
enzae, Branhamella catarrhalis, pathogenic streptococci,
certain enteric gram-negative rods, and perhaps oral
anaerobes are targeted by these prophylactic agents. The
efficacy of prophylaxis is dependent on the antimicrobial
spectrum of each agent and its ability to penetrate into
respiratory secretions. The rationale for prophylactic ther-
apy is the prevention of lower respiratory tract infections in
CF patients by these organisms. The danger in this strategy
is twofold. P. aeruginosa, perceived to be the most impor-
tant pathogen in CF lung disease, is resistant to these agents
(5), and elimination of competing flora may enhance its
growth. Secondly, the emergence of antimicrobial resistance
in organisms such as TD S. aureus during prophylaxis has
been demonstrated (3, 8; George and Hewling, Letter;
Lacey and Lewis, Letter).
Over a 1-year period at our two CF centers, we found that
20 of 39 patients who were positive for S. aureus and who
were receiving prophylactic TMP-SMX harbored TD S.
aureus. That is, they carried TMP-SMX-resistant organisms
as their predominant staphylococcal isolates. The patients
with TD S. aureus had received TMP-SMX for a signifi-
cantly longer period of time (P = 0.0067) than those who
were receiving TMP-SMX and harbored non-TD S. aureus.
Because of the technique used to detect TD S. aureus, the
percentage of patients with TD S. aureus on TMP-SMX
therapy may have been an underestimation. Our method, the
lack of growth on Mueller-Hinton agar, was dependent on
TD S. aureus being the predominant or only strain of S.
aureus present in the culture. If non-TD S. aureus were
present in high enough concentrations such that at least one
in five colonies picked for susceptibility was non-TD S.
aureus, then TD S. aureus would not be detected. Several
reports of TD S. aureus in CF patients have been published
in Great Britain (3, 8; George and Hewling, Letter; Lacey
and Lewis, Letter). Sparham and colleagues (8) reported
that 7 of 11 patients from whom S. aureus was recovered had
TD S. aureus. All seven had received TMP-SMX. Howden
reported that with a special medium, colistin-DNA-mannitol
agar, 8 of 12 CF children receiving TMP-SMX had TD S.
aureus recovered after a few days of therapy, whereas TD S.
aureus was not isolated from 13 patients who received
alternative therapies (3). These data suggest that emergence
of TMP-SMX resistance during therapy is a frequent prob-
lem in CF patients.
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The survival of TD S. aureus in the lung environment of
CF patients is not surprising. Bronchial secretions from CF
patients are usually purulent and microscopically contain
many deteriorating cells. The ability of S. aureus to produce
DNase which would degrade the DNA of deteriorating cells
would result in the release of thymidine. This thymidine
could then be used to support the growth of TD S. aureus.
Thymidine concentrations within lung secretions would have
to be relatively high since Stokes and Lacey (10) have shown
that a TD S. aureus strain underwent thymineless death in
vitro at thymidine concentrations of less than 5 ,ug/ml. The
optical density of TD S. aureus C-1003 dropped after initial
growth at low concentrations of thymidine ('6.25 ,ug/ml)
(Fig. 1), supporting this observation.
The importance of TD S. aureus from the perspective of
the clinical microbiologist is the difficulty in detecting this
organism on most laboratory media commonly used for S.
aureus isolation. Our data suggest that mannitol salt agar is
the medium of choice for isolation of TD S. aureus. How-
ever, the survey of CF centers by O. Tablan found that only
22 of 114 centers use this medium. Many centers rely on
either chocolate or 5% sheep blood agar for S. aureus
isolation. Because of the aberrant colony morphology seen
in this study with several of the TD S. aureus isolates on
these media, TD S. aureus might be confused with orga-
nisms which are generally thought to be normal
oropharyngeal flora, such as certain streptococci, hemophili,
or saprophytic Neisseria spp. This might result in the culture
being reported as negative for 5. aureus.
The role of TD S. aureus in pulmonary disease of CF
patients has not been established. However, it would seem
prudent that in CF centers in which TMP-SMX is used as a
long-term prophylactic agent, laboratories should use man-
nitol salt agar or medium enriched with thymidine to ensure
the isolation of this organism. Only then will we be able to
determine the role, if any, of this organism in the pulmonary
disease of CF patients.
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